ASH 2018 | ZUMA-1, JULIET andTRANSCEND trials: changing the treatment landscape for R/R NHL

David Maloney

David Maloney, MD, PhD, of the Fred Hutchinson Cancer Research Center, Seattle, WA, provides an overview of key updates in treatment for relapsed/refractory non-Hodgkin lymphoma (NHL), specifically the ZUMA-1 (NCT02348216), JULIET (NCT02445248), and TRANSCEND (NCT02631044) trials investigating the use of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel, respectively. Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA., Dr Maloney discusses the safety and efficacy, including PFS and CR rates from these trials.

Share this video